Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired viral kinetics and therapeutic response

Hepatology

Volumn 56, Issue 2, 2012, Pages 444-454

  Naggie, Susanna ^a   Osinusi, Anu ^b,c   Katsounas, Antonios ^c   Lempicki, Richard ^c   Herrmann, Eva ^d   Thompson, Alexander J ^a   Clark, Paul J ^a   Patel, Keyur ^a   Muir, Andrew J ^a   McHutchison, John G ^e   Schlaak, Joerg F ^f   Trippler, Martin ^f   Shivakumar, Bhavana ^b   Masur, Henry ^g   Polis, Michael A ^b   Kottilil, Shyam ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d SAIC FREDERICK INC   (United States)

^e GOETHE UNIVERSITY   (Germany)

^f GILEAD SCIENCES   (United States)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; INTERFERON; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ARTICLE; CELL DEATH; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA MICROARRAY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENOTYPING TECHNIQUE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INNATE IMMUNITY; LABORATORY TEST; MALE; MICROBIAL KINETICS; MIXED INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL KINETICS; VIRUS LOAD;

ADULT; ALBUMINS; ANTIVIRAL AGENTS; COHORT STUDIES; COINFECTION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; INTERFERON-ALPHA; INTERLEUKINS; MIDDLE AGED; PHARMACOGENETICS; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84864367453     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25647     Document Type: Article

References (28)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl. 1): 74-81.
2. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
3. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-1089.
4. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38: 128-133.
5. Ge D, Fellay J, Thompson A, Simon J, Shianna K, Urban T, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
6. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alfa and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
7. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alfa and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
8. Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24: F23-F29.
9. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. HEPATOLOGY 2010; 52: 1888-1896.
10. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
11. Dill MT, Duong FHT, Vogt JE, Bibert S, Bochud P, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031.
12. Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, et al. Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response. HEPATOLOGY 2012; 55: 20-29.
13. Kottilil S, Yan MY, Reitano KN, Zhang X, Lempicki R, Roby G, et al. Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. HEPATOLOGY 2009; 50: 34-45.
14. Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, Huang DW, et al. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 2006; 193: 1172-1177.
15. Rozenberg L, Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, et al. Therapeutic response to peg-IFN-alfa-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS 2009; 23: 2439-2450.
16. Shudo E, Ribeiro RM, Perelson AS. Modeling hepatitis C virus kinetics under therapy using pharmacokinetic and pharmacodynamic information. Expert Opin Drug Metab Toxicol 2009; 5: 321-332.
17. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. HEPATOLOGY 2007; 46: 16-21.
18. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. HEPATOLOGY 2003; 37: 1351-1358.
19. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modeling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432: 922-924.
20. Affonso de Araujo ES, Dahari H, Cotler SJ, Layden TJ, Neumann AU, Melo CE, et al. Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients. J Acquir Immune Defic Syndr 2011; 56: 95-99.
21. Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011; 55: 980-988.
22. Rallon NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011; 25: 1025-1033.
23. Golden-Mason L, Bambha KM, Cheng L, Howell CD, Taylor MW, Clark PJ, et al. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. HEPATOLOGY 2011; 54: 1559-1569.
24. Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA, et al Alfa-interferon and its effects on signal transduction pathways. J Cell Physiol. 2005; 202: 323-335.
25. Gonzalez VD, Landay AL, Sandberg JK. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol 2010; 135: 12-25.
26. Thomas D, Thio C, Martin M, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
27. Mannova P, Beretta L. J Virology 2005; 79: 8742-8749.
28. Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB. Genomic response to interferon-α in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. HEPATOLOGY 2006; 43: 961-972.